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Introduction
Current recommendations for the treatment of familial
Mediterranean fever (FMF) are based largely on the
observation of FMF patients receiving colchicine therapy
in childhood and young age. The adequate colchicine
therapy led to more and more patients survive to that
age. In addition, there are national peculiarities of FMF.
For example, in Armenia, even before the massive use
of colchicine therapy, many patients survived to middle
and old age.
Objectives
We have investigated the corse of FMF in middle and
old age, the incidence of miocardial infarction and the
outcomes in case of myocardial infarction.
Methods
Follow-up during 10-30 years.
Results
Our research has shown that the risk of amyloidosis
decreases with age, and the ability of colchicine to prevent
attacks of FMF increases with age. Our research has also
shown that in the absence of regular colchicine therapy
increases the risk of myocardial infarction. In addition,
myocardial infarction in patients with FMF is more severe,
with a higher risk of death. With age the incidence of
many diseases is increased, but their co-therapy with col-
chicine has not been studied.
Conclusion
To date, may be recommended in middle and old age to
take colchicine at a dosage that fully prevents the attacks
of FMF in young age. If treatment is initiated in middle
or old age, the dosage of colchicine should be higher
than necessary to control the attacks of illness and indi-
cators of inflammation. Untreated in young age FMF
should be considered as a risk factor for CHD. Patients
with FMF in the case of acute myocardial infarction
should be observed over a long time and prevention of
complications should be more intense. Urgently need to
be initiated the multi-center and national studies on the
combined treatment of FMF and the most common
diseases in middle and old age.
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